BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dianzani C, Foglietta F, Ferrara B, Rosa AC, Muntoni E, Gasco P, Della Pepa C, Canaparo R, Serpe L. Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an in vivo model. World J Gastroenterol 2017; 23(23): 4200-4210 [PMID: 28694660 DOI: 10.3748/wjg.v23.i23.4200] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Lechner K, Zeeshana M, Noack M, Ali H, Neurath M, Weigmanna B. Small but powerful: Will nanoparticles be the future state‐of‐the‐art therapy for IBD? Expert Opinion on Drug Delivery. [DOI: 10.1080/17425247.2022.2043847] [Reference Citation Analysis]
2 Wang CJ, Byun MJ, Kim S, Park W, Park HH, Kim T, Lee JS, Park CG. Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.02.028] [Reference Citation Analysis]
3 Prieto E, Cardiel MJ, Vispe E, Idoipe M, Garcia-Martin E, Fraile JM, Polo V, Mayoral JA, Pablo LE, Rodrigo MJ. Dexamethasone delivery to the ocular posterior segment by sustained-release Laponite formulation. Biomed Mater 2020;15:065021. [PMID: 32647098 DOI: 10.1088/1748-605X/aba445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
4 Khan AS, Shah KU, Mohaini MA, Alsalman AJ, Hawaj MAA, Alhashem YN, Ghazanfar S, Khan KA, Niazi ZR, Farid A. Tacrolimus-Loaded Solid Lipid Nanoparticle Gel: Formulation Development and In Vitro Assessment for Topical Applications. Gels 2022;8:129. [PMID: 35200510 DOI: 10.3390/gels8020129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Chen F, Liu Q, Xiong Y, Xu L. Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease. Int J Nanomedicine 2021;16:4225-37. [PMID: 34188471 DOI: 10.2147/IJN.S310952] [Reference Citation Analysis]
6 Ryan A, Patel P, O'Connor PM, Ross RP, Hill C, Hudson SP. Pharmaceutical design of a delivery system for the bacteriocin lacticin 3147. Drug Deliv Transl Res 2021;11:1735-51. [PMID: 33876405 DOI: 10.1007/s13346-021-00984-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Giron F, Pastó A, Tasciotti E, Abraham BP. Nanotechnology in the Treatment of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019;25:1871-80. [DOI: 10.1093/ibd/izz205] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
8 Van Looveren K, Wallaeys C, Libert C. Potential of glucocorticoids to treat intestinal inflammation during sepsis. Curr Opin Pharmacol 2020;53:1-7. [PMID: 31991314 DOI: 10.1016/j.coph.2019.12.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Leonard F, Srinivasan S, Liu X, Collnot E, Ferrari M, Lehr C, Godin B. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease. European Journal of Pharmaceutics and Biopharmaceutics 2020;151:61-72. [DOI: 10.1016/j.ejpb.2020.03.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Barahona MJ, Baratta V, Ollodart J, Mulligan D, Geibel JP. Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders. Future Med Chem 2019;11:847-55. [PMID: 30994367 DOI: 10.4155/fmc-2018-0313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
11 Jogpal V, Sanduja M, Dutt R, Garg V, Tinku. Advancement of nanomedicines in chronic inflammatory disorders. Inflammopharmacology 2022. [PMID: 35217901 DOI: 10.1007/s10787-022-00927-x] [Reference Citation Analysis]
12 Minakshi P, Kumar R, Ghosh M, Brar B, Barnela M, Lakhani P. Application of Polymeric Nano-Materials in Management of Inflammatory Bowel Disease. Curr Top Med Chem 2020;20:982-1008. [PMID: 32196449 DOI: 10.2174/1568026620666200320113322] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
13 Desoqi MH, El-Sawy HS, Kafagy E, Ghorab M, Gad S. Fluticasone propionate-loaded solid lipid nanoparticles with augmented anti-inflammatory activity: optimisation, characterisation and pharmacodynamic evaluation on rats. J Microencapsul 2021;38:177-91. [PMID: 33583315 DOI: 10.1080/02652048.2021.1887383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yang M, Zhang Y, Ma Y, Yan X, Gong L, Zhang M, Zhang B. Nanoparticle-based therapeutics of inflammatory bowel diseases: a narrative review of the current state and prospects. Journal of Bio-X Research 2020;3:157-73. [DOI: 10.1097/jbr.0000000000000078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Madamsetty VS, Mohammadinejad R, Uzieliene I, Nabavi N, Dehshahri A, García-Couce J, Tavakol S, Moghassemi S, Dadashzadeh A, Makvandi P, Pardakhty A, Aghaei Afshar A, Seyfoddin A. Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems. ACS Biomater Sci Eng 2022;8:1763-90. [PMID: 35439408 DOI: 10.1021/acsbiomaterials.2c00026] [Reference Citation Analysis]
16 Sharma M, Sharma S, Wadhwa J. Improved uptake and therapeutic intervention of curcumin via designing binary lipid nanoparticulate formulation for oral delivery in inflammatory bowel disorder. Artificial Cells, Nanomedicine, and Biotechnology 2019;47:45-55. [DOI: 10.1080/21691401.2018.1543191] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
17 Zafar A, Alruwaili NK, Imam SS, Yasir M, Alsaidan OA, Alquraini A, Rawaf A, Alsuwayt B, Anwer MK, Alshehri S, Ghoneim MM. Development and Optimization of Nanolipid-Based Formulation of Diclofenac Sodium: In Vitro Characterization and Preclinical Evaluation. Pharmaceutics 2022;14:507. [DOI: 10.3390/pharmaceutics14030507] [Reference Citation Analysis]
18 Cappellano G, Comi C, Chiocchetti A, Dianzani U. Exploiting PLGA-Based Biocompatible Nanoparticles for Next-Generation Tolerogenic Vaccines against Autoimmune Disease. Int J Mol Sci 2019;20:E204. [PMID: 30626016 DOI: 10.3390/ijms20010204] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 10.7] [Reference Citation Analysis]
19 Ryan A, Patel P, O'connor PM, Cookman J, Paul Ross R, Hill C, Hudson SP. Single versus double occupancy solid lipid nanoparticles for delivery of the dual-acting bacteriocin, lacticin 3147. European Journal of Pharmaceutics and Biopharmaceutics 2022. [DOI: 10.1016/j.ejpb.2022.05.016] [Reference Citation Analysis]
20 Brusini R, Varna M, Couvreur P. Advanced nanomedicines for the treatment of inflammatory diseases. Adv Drug Deliv Rev 2020;157:161-78. [PMID: 32697950 DOI: 10.1016/j.addr.2020.07.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 21.5] [Reference Citation Analysis]
21 Naeem M, Awan UA, Subhan F, Cao J, Hlaing SP, Lee J, Im E, Jung Y, Yoo J. Advances in colon-targeted nano-drug delivery systems: challenges and solutions. Arch Pharm Res 2020;43:153-69. [DOI: 10.1007/s12272-020-01219-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 13.5] [Reference Citation Analysis]
22 Mittal R, Patel AP, Jhaveri VM, Kay SS, Debs LH, Parrish JM, Pan DR, Nguyen D, Mittal J, Jayant RD. Recent advancements in nanoparticle based drug delivery for gastrointestinal disorders. Expert Opinion on Drug Delivery 2017;15:301-18. [DOI: 10.1080/17425247.2018.1420055] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
23 Limongi T, Susa F, Allione M, di Fabrizio E. Drug Delivery Applications of Three-Dimensional Printed (3DP) Mesoporous Scaffolds. Pharmaceutics 2020;12:E851. [PMID: 32911620 DOI: 10.3390/pharmaceutics12090851] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
24 Mohan LJ, Daly JS, Ryan BM, Ramtoola Z. The future of nanomedicine in optimising the treatment of inflammatory bowel disease. Scand J Gastroenterol 2019;54:18-26. [PMID: 30678499 DOI: 10.1080/00365521.2018.1563805] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]